This index provides a comprehensive mapping of therapeutic targets for 4R-tauopathies, specifically progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS/CBD). The page integrates the therapeutic pipeline, clinical trial status, and mechanism-to-treatment gaps to identify priority areas for research and development.
PSP and CBS represent the two major clinical syndromes within the 4R-tauopathy spectrum, sharing neuropathological features but differing in regional distribution and clinical presentation[1][2]. This index organizes therapeutic approaches by molecular target and maps them to the disease mechanisms they aim to address.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| MAPT (tau) mRNA | Antisense oligonucleotide (ASO) | Phase 1-2 | BIIB080 (MAPTRx), NIO752 | Phase 1 complete, CSF tau lowering demonstrated |
| MAPT splicing | Splice-modulating ASO | Preclinical | Multiple programs | Preclinical |
| MAPT transcription | Gene therapy | Preclinical | AAV-MAPT vectors | Preclinical |
Mechanism-to-Treatment Gap: ASO approaches have demonstrated the strongest pharmacodynamic signal in humans with dose-dependent CSF tau reduction[3]. However, delivery requires intrathecal administration, limiting practical accessibility. Next-generation oral or systemic delivery systems are needed.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Tau oligomerization | Small molecule | Phase 2-3 | LMTM (methylthioninium), GV1001 | Mixed efficacy signals |
| Tau filament assembly | Small molecule | Preclinical | Various compounds | Preclinical |
Mechanism-to-Treatment Gap: Aggregation inhibitors address the seed propagation mechanism critical to tau spreading. However, optimal blood-brain barrier penetration and adequate brain concentrations remain challenging. Early intervention may be required for efficacy.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Extracellular tau | Passive antibody (mid-region) | Phase 2 | Tilavonemab | Failed primary endpoint[4] |
| Extracellular tau | Passive antibody (N-terminal) | Phase 2 | Bepranemab | Ongoing[5] |
| Extracellular tau | Passive antibody | Phase 1-2 | JNJ-63733657, E2814 | Various stages |
| Phospho-tau (pSer396/404) | Active vaccine | Phase 1-2 | AADvac1 | Mixed efficacy |
Mechanism-to-Treatment Gap: Anti-tau antibodies have failed in PSP specifically, raising questions about epitope selection, target engagement timing, and whether extracellular neutralization addresses the core intracellular pathology. Next-generation approaches need 4R-tau-specific epitope targeting and better CNS penetration.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| O-GlcNAcylation | O-GlcNAcase (OGA) inhibitor | Phase 1-2 | LY3372689 (LOTUS) | Ongoing |
| Phosphorylation | Kinase inhibitors | Preclinical | GSK3β, CDK5 inhibitors | Preclinical |
| Acetylation | Acetyltransferase inhibitors | Preclinical | p300/CBP inhibitors | Preclinical |
Mechanism-to-Treatment Gap: OGA inhibitors aim to shift tau toward less pathological conformations by increasing O-GlcNAcylation. Early biomarker data suggest target engagement, but clinical efficacy remains to be demonstrated. The approach is attractive for chronic oral dosing.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Mitochondrial function | Coenzyme Q10 | Phase 2-3 | CoQ10 | Failed[6] |
| Mitochondrial biogenesis | PGC-1α activator | Preclinical | Various compounds | Preclinical |
| Complex I support | Small molecule | Preclinical | Various compounds | Preclinical |
Mechanism-to-Treatment Gap: Mitochondrial dysfunction is prominent in PSP pathology, but CoQ10 trials failed to show efficacy. This suggests either timing (too late in disease course) or target inadequacy (CoQ10 may not address the primary mitochondrial deficit).
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Microglia activation | CSF1R antagonist | Preclinical | PLX3397, PLX5622 | Preclinical |
| Complement activation | C1q inhibitor | Preclinical | Various antibodies | Preclinical |
| TREM2 signaling | TREM2 agonist | Preclinical | Various compounds | Preclinical |
Mechanism-to-Treatment Gap: Neuroinflammation is a prominent feature of PSP/CBS, but anti-inflammatory approaches have not been systematically tested in human trials. Timing and which inflammatory pathway to target remain unclear.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| BDNF signaling | TrkB agonist | Preclinical | Various small molecules | Preclinical |
| GDNF delivery | Gene therapy | Preclinical | AAV-GDNF | Preclinical |
| CNTF signaling | Protein delivery | Preclinical | CNTF derivatives | Preclinical |
Mechanism-to-Treatment Gap: Neurotrophic approaches face delivery challenges across the blood-brain barrier and ensuring proper distribution to affected brain regions. Gene therapy approaches are advancing but require surgical delivery.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Synaptic plasticity | PDE inhibitors | Preclinical | PDE4, PDE5 inhibitors | Preclinical |
| Excitotoxicity | NMDA modulation | Preclinical | Memantine derivatives | Preclinical |
| Synuclein interaction | Alpha-synuclein modulation | Preclinical | Various approaches | Preclinical |
Mechanism-to-Treatment Gap: Synaptic loss correlates with cognitive decline, but no synaptic protective therapies have reached clinical testing in PSP/CBS. Biomarkers for synaptic integrity are needed.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Dopamine replacement | Levodopa/carbidopa | Approved | Standard formulations | Limited response |
| Dopamine agonist | Pramipexole, rotigotine | Approved | Various | Limited response |
Mechanism-to-Treatment Gap: Levodopa provides modest and often transient benefit in PSP, less than in Parkinson's disease, reflecting significant non-dopaminergic pathology. No optimized PSP-specific dopaminergic regimens exist.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Pseudobulbar affect | Dextromethorphan/quinidine | Approved | Nuedexta | Used off-label |
| Depression | SSRIs | Approved | Various | Standard of care |
| Sleep disorder | Melatonin, modafinil | Approved | Various | Standard of care |
Mechanism-to-Treatment Gap: Non-motor symptoms significantly impact quality of life but are addressed with repurposed medications not optimized for PSP/CBS-specific pathophysiology.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| L-type calcium channel | Dihydropyridine antagonists | Preclinical | Various compounds | Preclinical |
| Ryanodine receptor | Dantrolene | Preclinical | Dantrolene | Preclinical |
| Mitochondrial calcium | MCU inhibitors | Preclinical | Various compounds | Preclinical |
Mechanism-to-Treatment Gap: Calcium dysregulation is prominent in PSP neurons but no clinical candidates have advanced beyond preclinical testing.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Autophagy induction | mTOR inhibition | Phase 2-3 | Rapamycin | Proposed |
| Autophagy induction | TFEB activation | Preclinical | TFEB agonists | Preclinical |
| Proteasome enhancement | USP30 inhibitors | Preclinical | Various compounds | Preclinical |
Mechanism-to-Treatment Gap: Enhancing tau clearance through autophagy is conceptually attractive but pharmacologic induction faces toxicity concerns and incomplete understanding of which clearance pathway to engage.
| Target | Modality | Development Stage | Key Programs | Clinical Status |
|---|---|---|---|---|
| Ketone metabolism | Ketogenic diet | Clinical observation | Dietary intervention | Observational |
| Glycolysis modulation | HK2 inhibitors | Preclinical | Various compounds | Preclinical |
| Astrocyte metabolism | Lactate transporters | Preclinical | Various compounds | Preclinical |
Mechanism-to-Treatment Gap: Metabolic deficits in PSP neurons are well-documented but metabolic therapies remain at early experimental stages.
| Category | Trial Count | Key Registrations |
|---|---|---|
| Tau immunotherapy | 8+ | Tilavonemab, Bepranemab, E2814 |
| Tau-lowering ASO | 3+ | BIIB080, NIO752 |
| OGA inhibition | 2+ | LY3372689 |
| Neuroprotection | 5+ | AMX0035, CoQ10 |
| symptomatic/supportive | 15+ | Various |
| Priority Rank | Target Category | Modality | Clinical Readiness | Gap Severity |
|---|---|---|---|---|
| 1 | Tau production (MAPT) | ASO | Phase 1-2 | Delivery method |
| 2 | Tau aggregation | Small molecule | Phase 2-3 | Brain penetration |
| 3 | Tau immunotherapy | Antibody | Phase 2 | Epitope selection |
| 4 | O-GlcNAcase | Inhibitor | Phase 1-2 | Clinical efficacy |
| 5 | Neuroinflammation | Various | Preclinical | Target selection |
| 6 | Autophagy enhancement | Small molecule | Preclinical | Safety/efficacy |
| 7 | Mitochondrial function | Various | Phase 2 | Failed trials |
| 8 | Neurotrophic support | Gene therapy | Preclinical | Delivery |
Clinical diagnosis of progressive supranuclear palsy: the MDS criteria. Movement Disorders. 2017. ↩︎
Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013. ↩︎
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer disease. Nature Medicine. 2023. ↩︎
Tilavonemab for progressive supranuclear palsy. Nature Medicine. 2024. ↩︎
Bepranemab for PSP and CBD. Lancet Neurology. 2024. ↩︎
Coenzyme Q10 in progressive supranuclear palsy. Movement Disorders. 2023. ↩︎